Browsing by Author "Petekkaya E."

Now showing 1 - 4 of 4

Comparative study of the volume of the temporal lobe sections and neuropeptide effect in Alzheimer’s patients and healthy persons
(2021-01-01) Petekkaya E.; Burakgazi G.; Kuş B.; Melek İ.M.; Arpacı A.
Aim: The aim of this study was to make a volumetric comparison of some medial temporal lobe structures and neuropeptides between the patients of Alzheimer’s disease (AD) and healthy individuals. Method: The study comprised of a group of patients diagnosed with mild AD (n:15) and a Control group (n:15) (16 females, 14 males, mean age:72.90 ± 4.50). Voxel-based morphometry and MRICloud analyses were performed on the MR images taken in 3D measurements of gray matter volumes of all subjects. Following a 10-minute hug test, blood samples were taken from all participants for oxytocin (OT) and arginine vasopressin (AVP) analyses. Results: The patient group had a statistically lower right hippocampus volume (p = 0.004) and OT values (p = 0.028) than the Control group. OT signal values increased with a volume increase in the right parahippocampal gyrus (PHG_R), and OT conc. and AVP conc. values increased with increasing volume of the PHG_R. Conclusion: It is suggested that the right hippocampus, right fusiform gyrus, left amygdala, left parahippocampal gyrus, and left entorhinal cortex atrophies can be used as predictors in the early diagnosis of AD. The positive correlation between PHG_R and neuropeptides showed the need to investigate the PHG and OT function more deeply.
Comparison of the protective effects of selective endothelin-a receptor antagonist, ambrisentan, and dual endothelin-A/B receptor antagonist, Bosentan, in experimental renal ischemia reperfusion injury
(2020-01-01) Kazimoglu H.; Uysal E.; Dokur M.; Gurer A.O.; Batcioglu K.; Uyumlu B.A.; Petekkaya E.; Karadag M.
AIM: This study aims to compare the protective effects of ambrisentan, a selective endothelin typeA receptor antagonist, and bosentan, a dual endothelin typeA/B receptor antagonist, on experimental renal ischemia reperfusion injury. METHOD: The study sample consisted of 21 female rats, which were divided into 3 groups: Control, Ambrisentan and Bosentan. For the ischemia-reperfusion injury model, left-kidney nephrectomy was performed after sacrifi cing the animals. In the immunohistochemical examination, caspase-3 was examined, and then the apoptotic index was determined. In the biochemical examination, the activities of malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase, and the levels of nitrite (NOx), TNF-α, and IL-1β were determined. RESULTS: There were statistically signifi cant differences between the groups in terms of total injury score grade in range of 0-3 (p=0.001). The glomerular and tubular apoptotic indices were higher in the control group as compared to those of the ambrisentan and bosentan groups (p=0.001). There were no statistically signifi cant differences in terms of SOD, CAT, GPx, MDA, IL-1β and TNF-α measurements among the groups (p>0.05). CONCLUSIONS: In the experimentally created renal ischemia reperfusion model, both ambrisentan and bosentan increased the NOx level, decreased the apoptosis, and protected the kidney from renal ischemia reperfusion injury. However, no signifi cant superiority was found between ambrisentan and bosentan in terms of their protective effects (Tab. 3, Fig. 2, Ref. 31). Text in PDF www.elis.sk.
Possible role of endocannabinoids in olfactory and taste dysfunctions in Alzheimer's and Parkinson's patients and volumetric changes in the brain
(2022-06-01) Petekkaya E.; Kuş B.; Doğan S.; Bayaroğulları H.; Mutlu T.; Murat Melek İ.; Arpacı A.
The purpose of this study is to determine the volumes of primary brain regions associated with smell and taste in Alzheimer's and Parkinson's patients and healthy controls using MR imaging and examine volumetric changes in comparison to smell/taste questionnaire and test results and endocannabinoid (EC) levels. The study included 15 AD patients with mild cognitive dysfunction scored as 18 ≤ MMSE ≤ 23, 15 PD patients with scores of 18 < MoCA < 26 and 18 ≤ MMSE ≤ 23, and 15 healthy controls. A taste and smell questionnaire was given to the participants, and their taste and smell statuses were examined using the Sniffin’ Sticks smell identification test and Burghart Taste Strips. EC levels were analyzed in the blood serum samples of the participants using the ELISA method. The volumes of the left olfactory bulb (p = 0.001), left amygdala (p = 0.004), left hippocampus (p = 0.008), and bilateral insula (left p = 0.000, right p = 0.000) were significantly smaller in the Alzheimer's patients than the healthy controls. The volumes of the left olfactory bulb (p = 0.001) and left hippocampus (p = 0.009) were significantly smaller in the Parkinson's patients than the healthy controls. A significant correlation was determined between volume reduction in the left Rolandic operculum cortical region and taste dysfunction. EC levels were significantly higher in both AD (p = 0.000) and PD (p = 0.006) in comparison to the controls. Our results showed that volumetric changes occur in the brain regions associated with smell and taste in Alzheimer's and Parkinson's patients. It was observed that ECs played a role in these volumetric changes and the olfactory and taste dysfunctions of the patients.
Possible Role of Endocannabinoids in Olfactory and Taste Dysfunctions in COVID-19 Patients and Volumetric Changes in the Brain
(2022-10-01) Ergül Z.; Kaptan Z.; Kars A.; Biçer G.; Kılınç Ç.; Petekkaya E.; Çöplü N.
Introduction: COVID-19 infection develops neurologic symptoms such as smell and taste loss. We aimed to determine the volumetric changes in the brain and correlation of possible related biochemical parameters and endocannabinoid levels after COVID-19 recovery. Methods: Brain magnetic resonance images of recovered COVID-19 patients and healthy volunteers, whose olfactory and gustatory scores were obtained through a questionnaire, were taken, and the volumes of the brain regions associated with taste and smell were measured by automatic and semiautomatic methods. Endocannabinoids (EC), which are critical in the olfactory system, and vitamin B12, zinc, iron, ferritin, thyroid-stimulating hormone (TSH), and thyroxine (T4) levels, which are reported to have possible roles in olfactory disorders, were measured in peripheral blood. Results: Taste and smell disorder scores and EC levels were found to be higher in recovered COVID-19 patients compared to controls. EC levels were negatively correlated with bilateral entorhinal cortex (ENT) volumes in the COVID-19 group. Subgenual anterior cingulate cortex volumes showed correlations with gustatory complaints and ferritin in recovered COVID-19 patients. Conclusions: The critical finding of our study is the high EC levels and negative correlation between EC levels and left ENT volumes in recovered COVID-19 patients. Implications: It is possible that ECs are potential neuromodulators in many conditions leading to olfactory disorders, including COVID-19.